BMYBristol-Myers Squibb CompanyLarge cap · $121.18B · FY ending 2025-12-31
$59.34+3.06% · 2026-07-13 · EOD
62/100 composite
A transparent blend of the four reads below — each opens into the tool it comes from. Not advice.Quality84
margins & F-ScoreValue57
P/E 17.2 · 85% of 12-mo rangeMomentum62
golden · price above 200-daySmart Money47
quiet · 0 funds · 0P/1S insidersBullish stackGolden crossAbove 200-day
vs S&P 500-2.5%
6-mo excess Trailing performance1M +6.7%
3M +1.2%
6M +6.2%
YTD +11.0%
1Y +22.3%
P/E vs its last 12 months (our price history): 12.3 low → 18.0 high
Current price sits at the 85th percentile of that window — near the top (richer). We only compare against the price history we own (no paid multi-year multiples — nothing invented).
Piotroski F7/9
fundamental strength ROIC = NOPAT ÷ (debt + equity − cash), using an effective tax rate of 24%. Annual figures from SEC XBRL.
Dividend & capital return
Payout ratio71.5%
stretched Shareholder yield4.2%
dividends + buybacks Annual figures from SEC cash-flow statements. Shareholder yield = total cash returned ÷ market cap.
Quiet0P / 1S insiders · 0 funds hold · 0 Congress buys
Recent insidersElkins David V · EVP, Chief Financial OfficerSELL$1.9M
Bhealth · 84/100
Self-fundingSelf-funding — profitable · generates cash
No red flags from its filings.
Educational tools — not financial advice. Fundamentals from SEC EDGAR (XBRL); prices are end-of-day (Databento). Scores are a transparent blend of the components shown, computed on our own data — a research aid, not a recommendation.